Introduction/Background Ovarian cancer affects many women worldwide. It is the most lethal gynecologic cancer. On the other hand, paracetamol is one of the most used analgesics in daily settings. Results from previous studies are diverse regarding its potential effect on the risk of ovarian cancer. This study aimed to determine the effect of paracetamol on ovarian cancer risk.

Methodology PubMed, Scopus, and Cochrane were searched for potential articles. This systematic review was written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 statement. Eligible articles were observational studies available in English, published from January 2003 - November 2023. Studies comparing previous usage of paracetamol in healthy populations and ovarian cancer patients were selected. The risk of bias was assessed using Risk Of Bias In Non-randomized Studies - of Exposures (ROBINS-E).

Results A total of 6934 articles were screened. After removing duplication, 460,881 women across nations participated in nine different observational studies. The meta-analysis showed that paracetamol is associated with decreased risk of ovarian cancer OR 0.91 95% CI 0.87–0.95, p<0.0001. However, heterogeneity was observed (I2 = 65%).

Conclusion The use of paracetamol as an analgesic can be beneficial as it has a protective effect on developing ovarian cancer.

Disclosures All authors declare there is no conflict of interests.